Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R

Targeting Alterations in the RAF–MEK Pathway

(2019) Rona Yaeger et al.   Cancer Discovery

Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway

(2019) Romi Gupta et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Guidelines for optimized gene knockout using CRISPR/Cas9

(2019) Claude Van Campenhout et al.   BIOTECHNIQUES

CRISPR/Cas9-based knockout pipeline for reverse genetics in mammalian cell culture

(2019) Aleksandra Spiegel et al.   METHODS

Ras-ERK1/2 signalling promotes the development of osteosarcoma through regulation of H4K12ac through HAT1

(2019) Jingzhe Zhang et al.   Artificial Cells Nanomedicine and Biotechnology

HAT1 Coordinates Histone Production and Acetylation via H4 Promoter Binding

(2019) Joshua J. Gruber et al.   MOLECULAR CELL

Genetic alterations in main candidate genes during melanoma progression

(2018) Maria Cristina Sini et al.   Oncotarget

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

(2018) Feifei Liu et al.   Acta Pharmaceutica Sinica B

Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine

(2017) Liang Cheng et al.   MODERN PATHOLOGY

Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines

(2017) Bradley Garman et al.   Cell Reports

Negative feedback regulation of the ERK1/2 MAPK pathway

(2016) David Lake et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120

(2016) S.-H. Chen et al.   Cancer Discovery

Ultraviolet Radiation Exposure and Its Impact on Skin Cancer Risk

(2016) Meg Watson et al.   Seminars in Oncology Nursing

Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade

(2015) W. T. Iams et al.   CLINICAL CANCER RESEARCH

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

(2015) Douglas B. Johnson et al.   EUROPEAN JOURNAL OF CANCER

BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model

(2015) Daniele Perna et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BRAF gene: From human cancers to developmental syndromes

(2015) Muhammad Ramzan Manwar Hussain et al.   SAUDI JOURNAL OF BIOLOGICAL SCIENCES

Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma

(2014) A. M. Menzies et al.   CLINICAL CANCER RESEARCH

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

(2014) Chong Sun et al.   NATURE

Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice

(2013) L Heinzerling et al.   BRITISH JOURNAL OF CANCER

Resistance to BRAF-targeted therapy in melanoma

(2013) Ryan J. Sullivan et al.   EUROPEAN JOURNAL OF CANCER

Molecular networks in melanoma invasion and metastasis

(2013) Ewa Aladowicz et al.   Future Oncology

Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors

(2013) E. J. Morris et al.   Cancer Discovery

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma

(2013) Jessie Villanueva et al.   Cell Reports

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance

(2012) A. M. Alcala et al.   CLINICAL CANCER RESEARCH

Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance

(2012) Roel H. Wilting et al.   DRUG RESISTANCE UPDATES

The role of BRAF V600 mutation in melanoma

(2012) Paolo A Ascierto et al.   Journal of Translational Medicine

BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer

(2012) N. Awasthi et al.   MOLECULAR CANCER THERAPEUTICS

ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors

(2012) G. Hatzivassiliou et al.   MOLECULAR CANCER THERAPEUTICS

MAP kinase signaling and inhibition in melanoma

(2012) R J Sullivan et al.   ONCOGENE

Histone acetyltransferase 1: More than just an enzyme?

(2011) Mark R. Parthun   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options

(2011) J. Villanueva et al.   CANCER RESEARCH

BRAFV600E: Implications for Carcinogenesis and Molecular Therapy

(2011) E. R. Cantwell-Dorris et al.   MOLECULAR CANCER THERAPEUTICS

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

(2008) K. S.M. Smalley et al.   MOLECULAR CANCER THERAPEUTICS